PROLOR Biotech to Host Investor Conference Call

NES-ZIONA, Israel, May 16, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will host an investor conference call and webcast on May 19, 2011 to review recently announced corporate developments, including the positive interim results from the company's Phase II trial of hGH-CTP, its long-acting version of human growth hormone.

A question-and-answer session will follow management's discussion.  All interested parties are encouraged to listen to the live conference call or live or archived webcast.

The conference call and webcast will begin at noon EDT.  To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit the Investors section of PROLOR's website at www.prolor-biotech.com.  

Those investors who prefer to participate by telephone, or who want to ask questions during the conference call, should dial the following number approximately 10 minutes prior to the scheduled start time and request to join the PROLOR Biotech call at: 1-800-860-2442.

A copy of the company's updated corporate presentation, which includes an interim analysis of data from the Phase II trial of hGH-CTP, is currently available at the Investors section of PROLOR's website at www.prolor-biotech.com/?CategoryID=216

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is in Phase II clinical development, and Factor IX, Factor VII, interferon beta and erythropoietin, which are in preclinical development, as well as an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis.  For more information, visit www.prolor-biotech.com.

PROLOR CONTACT:

MEDIA CONTACT:

Shai Novik, President

Barbara Lindheim

PROLOR Biotech, Inc.

GendeLLindheim BioCom Partners

Tel: +1 866 644-7811

+1 212 918-4650

Email: [email protected]

[email protected]



SOURCE PROLOR Biotech, Inc.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.